BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33283733)

  • 41. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.
    Kulasekararaj AG; Jiang J; Smith AE; Mohamedali AM; Mian S; Gandhi S; Gaken J; Czepulkowski B; Marsh JC; Mufti GJ
    Blood; 2014 Oct; 124(17):2698-704. PubMed ID: 25139356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
    Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes.
    Shi C; Gong S; Wu A; Yang S; Zou D; Zhang Y; Wu N; Ma C; Shi S; Chen Y; Wu Y; Zheng X; Huang Z; Ding J; Ouyang G; Mu Q
    BMC Cancer; 2022 Jan; 22(1):127. PubMed ID: 35100989
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Tara S; Isshiki Y; Nakajima-Takagi Y; Oshima M; Aoyama K; Tanaka T; Shinoda D; Koide S; Saraya A; Miyagi S; Manabe I; Matsui H; Koseki H; Bardwell VJ; Iwama A
    Blood; 2018 Dec; 132(23):2470-2483. PubMed ID: 30228234
    [No Abstract]   [Full Text] [Related]  

  • 46. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic alterations of the cohesin complex genes in myeloid malignancies.
    Thota S; Viny AD; Makishima H; Spitzer B; Radivoyevitch T; Przychodzen B; Sekeres MA; Levine RL; Maciejewski JP
    Blood; 2014 Sep; 124(11):1790-8. PubMed ID: 25006131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
    Cooper JP; Khajaviyan S; Smith SD; Maloney DG; Shustov AR; Warren EH; Soma LA; Lynch RC; Ujjani C; Till B; Halpern AB; Gopal AK; Deeg HJ; Scott BL; Shadman M
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):390-395. PubMed ID: 30948330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CNS tumor with CREBBP::BCORL1 Fusion and pathogenic mutations in BCOR and CREBBP: expanding the spectrum of BCOR-altered tumors.
    Barresi V; Cardoni A; Miele E; Pedace L; Masotto B; Nardini C; Barresi S; Rossi S
    Acta Neuropathol Commun; 2024 Jan; 12(1):8. PubMed ID: 38216991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
    Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
    PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Montalban-Bravo G; Takahashi K; Patel K; Wang F; Xingzhi S; Nogueras GM; Huang X; Pierola AA; Jabbour E; Colla S; Gañan-Gomez I; Borthakur G; Daver N; Estrov Z; Kadia T; Pemmaraju N; Ravandi F; Bueso-Ramos C; Chamseddine A; Konopleva M; Zhang J; Kantarjian H; Futreal A; Garcia-Manero G
    Oncotarget; 2018 Feb; 9(11):9714-9727. PubMed ID: 29515765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Mutation analysis of 77 patients with normal-karyotype myelodysplastic syndrome].
    Qin W; Chen M; Cai X; Chao H; Liu J; Jiang N; Zhou M; Lu X; Chen S; Zhang R; He C; Wang Q
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Sep; 36(9):857-861. PubMed ID: 31515775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Yu J; Li Y; Li T; Li Y; Xing H; Sun H; Sun L; Wan D; Liu Y; Xie X; Jiang Z
    Exp Hematol Oncol; 2020; 9():2. PubMed ID: 31921515
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
    Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of Novel Insertions and Deletions in Haematopoietic Stem/Progenitor Cells in de novo Myelodysplastic Syndromes.
    Bandara M; Goonasekera H; Dissanayake V
    Int J Mol Cell Med; 2021; 10(3):228-233. PubMed ID: 35178361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Analysis of mutations of 14 genes among 87 patients with myelodysplastic syndrome].
    Zhou X; Jin H; Mu Q; Sheng L; Lai B; Zhu H; Ouyang G
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):953-956. PubMed ID: 31598934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
    Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
    Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
    Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Somatic Mutations of Acquired Aplastic Anemia].
    Zhang ML; Chen WS; Han B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Jun; 44(3):491-496. PubMed ID: 35791949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.